Inhibrx, Inc. (INBX)

NASDAQ: INBX · IEX Real-Time Price · USD
11.72
+0.44 (3.90%)
Jun 24, 2022 4:00 PM EDT - Market closed
3.90%
Market Cap 457.52M
Revenue (ttm) 7.27M
Net Income (ttm) -93.73M
Shares Out 39.04M
EPS (ttm) -2.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 542,423
Open 11.48
Previous Close 11.28
Day's Range 10.33 - 11.80
52-Week Range 7.67 - 47.90
Beta n/a
Analysts Buy
Price Target 47.94 (+309.0%)
Earnings Date Aug 8, 2022

About INBX

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic ... [Read more...]

Industry Biotechnology
IPO Date Aug 19, 2020
Employees 106
Stock Exchange NASDAQ
Ticker Symbol INBX
Full Company Profile

Financial Performance

In 2021, Inhibrx's revenue was $7.23 million, a decrease of -43.89% compared to the previous year's $12.89 million. Losses were -$81.77 million, 7.41% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for INBX stock is "Buy." The 12-month stock price forecast is 47.94, which is an increase of 309.04% from the latest price.

Price Target
$47.94
(309.04% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting

SAN DIEGO , May 19, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that it w...

Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder

Inhibrx Inc (NASDAQ: INBX) announced topline results from a Phase 1 clinical trial of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency (AA...

INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential t...

Topline results from the Phase 1 study showed a favorable safety and tolerability profile with no drug-related severe or serious adverse events. Topline data from the multiple ascending dose cohorts of ...

Inhibrx, Inc. (INBX) Reports Q1 Loss, Misses Revenue Estimates

Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -29.03% and 7.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Inhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

SAN DIEGO , May 9, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today reported financial results ...

Inhibrx, Inc. (INBX) Soars 15%: Is Further Upside Left in the Stock?

Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...

Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101

SAN DIEGO , April 25, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced the formation ...

Inhibrx to Present INBRX-101 Data at ATS 2022 Annual Meeting

SAN DIEGO , April 5, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that lat...

Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting

SAN DIEGO , March 24, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that da...

Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

SAN DIEGO, March 3, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced that the U.S. Fo...

Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights

SAN DIEGO, Feb, 28, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today reported financial results...

Inhibrx Announces Amended Loan Agreement with Oxford

SAN DIEGO, Feb. 22, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced that it has amen...

Inhibrx Shares Interim Data On INBRX-106 - Keytruda Combo Therapy In Solid Tumors

Inhibrx Inc (NASDAQ: INBX) announced initial results from Part 3 (combination dose escalation) of the Phase 1 trial of INBRX-106 combined with Keytruda for solid tumors.  The dose of INBRX-106 was escal...

Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combinat...

SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced initial results f...

Here's What Could Help Inhibrx, Inc. (INBX) Maintain Its Recent Price Strength

Inhibrx, Inc. (INBX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma

SAN DIEGO, Dec. 1, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced that the U.S. Foo...

Wall Street Analysts Predict a 32% Upside in Inhibrx, Inc. (INBX): Here's What You Should Know

The mean of analysts' price targets for Inhibrx, Inc. (INBX) points to a 32% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys...

Inhibrx, Inc. (INBX) Reports Q3 Loss, Tops Revenue Estimates

Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of 5.26% and 153.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today reported financial results ...

Inhibrx, Inc. (INBX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Inhibrx, Inc. (INBX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Inhibrx Announces Presentations at SITC 2021

SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that the C...

Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences

SAN DIEGO, Nov. 1, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that the C...

Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D....

SAN DIEGO, Oct. 28, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), announced the appointment of three key executives: David Matly, M.B.A., as Chief Commercial Officer; David Kao, PharmD, M.B.A.

Here's Why Inhibrx Stock Is on the Move Today

The first clinical trial results for a candidate for the treatment of alpha-1 antitrypsin deficiency look highly encouraging.

INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potenti...

SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, today announced interim r...